These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35791496)

  • 21. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
    Mariottini A; Bertozzi A; Marchi L; Di Cristinzi M; Mechi C; Barilaro A; Massacesi L; Repice AM
    J Neurol; 2022 Jun; 269(6):2840-2847. PubMed ID: 35239006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis.
    Gyang TV; Evans JP; Miller JS; Alcorn K; Peng J; Bell EH; Zeng C; Gumina R; Liu SL; Segal BM
    Mult Scler J Exp Transl Clin; 2022; 8(1):20552173221087357. PubMed ID: 35342640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study.
    Bsteh G; Hegen H; Traxler G; Krajnc N; Leutmezer F; Di Pauli F; Kornek B; Rommer P; Zulehner G; Dürauer S; Bauer A; Kratzwald S; Klotz S; Winklehner M; Deisenhammer F; Guger M; Höftberger R; Berger T
    Eur J Neurol; 2022 May; 29(5):1538-1544. PubMed ID: 35102646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome after COVID-19 infection in multiple sclerosis: a nation-wide multicenter matched-control study.
    Bsteh G; Assar H; Gradl C; Heschl B; Hiller MS; Krajnc N; Di Pauli F; Hegen H; Traxler G; Leutmezer F; Wipfler P; Zulehner G; Guger M; Enzinger C; Berger T;
    Eur J Neurol; 2022 Jun; ():. PubMed ID: 35751475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis.
    Rose DR; Mahadeen AZ; Carlson AK; Planchon SM; Sedlak J; Husak S; Bermel RA; Cohen JA; Moss BP
    Mult Scler J Exp Transl Clin; 2021 Oct; 7(4):20552173211057110. PubMed ID: 34925875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
    Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
    Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review.
    Bazylewicz M; Gudowska-Sawczuk M; Mroczko B; Kochanowicz J; Kułakowska A
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
    Räuber S; Willison A; Korsen M; Kölsche T; Golombeck KS; Plaack B; Schüller J; Huntemann N; Rolfes L; Schroeter CB; Nelke C; Regner-Nelke L; Förster M; Ringelstein M; Barnett MH; Hartung HP; Aktas O; Albrecht P; Ruck T; Melzer N; Meuth SG; Kremer D
    Front Immunol; 2022; 13():1037214. PubMed ID: 36618356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment.
    Woopen C; Dunsche M; Haase R; Raposo C; Pedotti R; Akgün K; Ziemssen T
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36224045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild-to-moderate COVID-19 in multiple sclerosis: A retrospective cohort study.
    Jin H; Geiger C; Jessop N; Pedotti R; Raposo C; Whitley L; Brown JS; Muros-Le Rouzic E
    Mult Scler Relat Disord; 2023 Nov; 79():104943. PubMed ID: 37716211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
    Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic.
    Todorović S; Vojinović S; Savić D; Aleksić D; Danilović M
    Acta Neurol Belg; 2024 Apr; 124(2):447-455. PubMed ID: 37962785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breakthrough COVID-19 in people with multiple sclerosis on disease modifying treatments: Is it still a severe disease?
    Immovilli P; Schiavetti I; Franceschini A; De Mitri P; Gelati L; Rota E; Guidetti D
    Mult Scler Relat Disord; 2024 May; 85():105547. PubMed ID: 38518506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
    Smith JB; Gonzales EG; Li BH; Langer-Gould A
    JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study.
    Sancho-Saldaña A; Gil-Sánchez A; González-Mingot C; Peralta S; Solana MJ; Torres P; Juanes A; Quibus L; Ruiz E; Sanpedro E; Quirant-Sánchez B; Martínez-Cáceres E; Ramo Tello C; Presas-Rodríguez S; García Rubio S; Baron BP; Ramió-Torrentà L; Sotoca J; González-Suárez I; Eichau S; Prieto-González JM; Blasco Quilez MR; Sabín-Muñoz J; Sánchez-López AJ; Llorens Calatayud G; Calles C; Sempere ÁP; Garcés M; Carmona O; Moral E; Hervás JV; Blanco Y; Sola-Valls N; Tellez Lara N; Forero L; Brieva L
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.
    Zabalza A; Arrambide G; Tagliani P; Cárdenas-Robledo S; Otero-Romero S; Esperalba J; Fernandez-Naval C; Trocoli Campuzano J; Martínez Gallo M; Castillo M; Bonastre M; Resina Sallés M; Beltran J; Carbonell-Mirabent P; Rodríguez-Barranco M; López-Maza S; Melgarejo Otálora PJ; Ruiz-Ortiz M; Pappolla A; Rodríguez Acevedo B; Midaglia L; Vidal-Jordana A; Cobo-Calvo A; Tur C; Galán I; Castilló J; Río J; Espejo C; Comabella M; Nos C; Sastre-Garriga J; Tintore M; Montalban X
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients.
    Zanetta C; Rocca MA; Filippi M
    Expert Rev Clin Immunol; 2022 May; 18(5):495-512. PubMed ID: 35395927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.
    Zaloum SA; Wood CH; Tank P; Upcott M; Vickaryous N; Anderson V; Baker D; Chance R; Evangelou N; George K; Giovannoni G; Harding KE; Hibbert A; Ingram G; Jolles S; Kang AS; Loveless S; Moat SJ; Richards A; Robertson NP; Rios F; Schmierer K; Willis M; Dobson R; Tallantyre EC
    Mult Scler; 2023 Jul; 29(8):979-989. PubMed ID: 37431627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations.
    Pugliatti M; Berger T; Hartung HP; Oreja-Guevara C; Bar-Or A
    Curr Opin Neurol; 2022 Jun; 35(3):319-327. PubMed ID: 35674075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.